Tag: Health Costs
Major Drug Companies Agree to Price Negotiations With U.S. Government
Ten drugs have been chosen for price negotiations by the Centers for Medicare & Medicaid Services
Extended-Release Buprenorphine Not Necessarily Cost-Effective
Extended-release buprenorphine not cost-effective when transmucosal buprenorphine is available for treatment of OUD
Economic Burden of Youth Violence Reached $122 Billion in 2020
Total annual economic burden of youth violence 17 percent higher in 2020 due to increase in youth homicides
Availability of CVD Meds Varies by Low-Cost Generic Program
Variation in coverage seen by program, drug, and cardiovascular disease condition
OOP Costs Often Exceed Discount Card Pricing for Select Generics
OOP payments exceeded Amazon and GoodRx prices for 40 and 79 percent of prescriptions assumed to be in deductible phase
Higher Administrative Payment Burden Causes Delays in Cancer Care
Younger patients, African American patients appear to have more cost-related delays/nonadherence
Rates of Tx Retention for Rifaximin Low Despite Benefits for Hepatic Encephalopathy
Lower treatment retention rates seen with 30-day, out-of-pocket costs ≥$150
Racial Disparities Seen for Cost of Unplanned Care After Breast Reconstruction
However, race is not a significant predictor of unplanned hospital visits
Nonpediatric Specialties Face Smaller Return Margins for HPV Vaccine Costs
Net returns from HPV vaccine cost reimbursements lowest for family physicians, highest for pediatricians
Private Equity Ownership Tied to Higher Costs to Patients
Furthermore, review found mixed to harmful impacts on quality of care
